The role of alendronate in osteoporosis patients undergoing PLIF .
Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial
J Neurosurg Spine. 2011 Apr;14(4):500-7. doi: 10.3171/2010.11.SPINE10245. Epub 2011 Jan 2840 osteoporosis patients undergoing single-level posterior lumbar interbody fusion were randomized to receive alendronate or vitamin D (alfacalcidol) to determine the impact of bisphosphonates on the spinal fusion recovery process. Following clinical, radiographic, and biochemical evaluations over a 12 month period, the results indicated that greater solid fusion, less cage subsidence, and no vertebral compression fractures were observed in the alendronate group, although bone formation and bone resorption markers were decreased with alendronate therapy.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
